A product of Philadelphia’s Curtis Institute and now lecturer/instructor at Boston University and Bard College, Zlabys’ ...

Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after ...

Pat Barker’s third novel in her multi-book reevaluation of the Trojan War follows Cassandra on her ill-fated trip to ...

I love this work. I love what I'm doing. It's so cool' Feature The Voyager probes have entered a new phase of operations. As ...

NASA has confirmed that after a pause in communications with Voyager 1 in late October, the spacecraft has regained its voice and resumed regular operations. Voyager unexpectedly turned off its ...

Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in ...

Wedbush has assumed coverage of Voyager Therapeutics (VYGR) with an outperform rating, highlighting the company’s TRACER ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) was the target of a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling ...

The new spacecraft will carry on the legacy of the Voyager program, which launched two probes in 1977 to explore Earth’s neighboring planets. The Interstellar Probe will feature modern instruments to ...

Voyager 1, which has traveled further from Earth than any other human-made object, has resumed contact after a brief period of silence. Last month, on October 19, Voyager 1 stopped sending signals ...

Citi initiated coverage of Voyager Therapeutics (VYGR) with a Buy rating and $12 price target Voyager is an early clinical-staged biotech ...